A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
A case report described an infant with concurrent HDFN and SMA who was succesfully treated with an onasemnogene abeparvovec infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback